References
- Gayle HD, Hill GL. Global impact of human immunodeficiency virus and AIDS. Clin Microbiol Rev. 2001;14:327–335.
- WHO. The top 10 causes of death (accessed 17 March 2015). Available from: http://www.who.int/mediacentre/factsheets/fs310/en/
- WHO. HIV/AIDS (accessed 17 March 2015). Available from: http://www.who.int/mediacentre/factsheets/fs360/en/
- Calmy A, Ford N, Hirschel B, et al. HIV viral load monitoring in resource-limited regions: optional or necessary? Clin Infect Dis. 2007;44:128–134.
- Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998;338:853–860.
- Kumarasamy N, Flanigan TP, Mahajan AP, et al. Monitoring HIV treatment in the developing world. Lancet Infect Dis. 2002;2:656–657.
- Bagchi S, Kempf MC, Westfall AO, et al. Can routine clinical markers be used longitudinally to monitor antiretroviral therapy success in resource-limited settings? Clin Infect Dis. 2007;44:135–138.
- Bracciale L, Di Giambenedetto S, Colafigli M, et al. Virological suppression reduces clinical progression in patients with multiclass-resistant HIV type 1. AIDS Res Hum Retroviruses. 2009;25:261–267.
- Fauci AS, Lane HC. Human immunodeficiency virus: AIDS and related disorders. In: Fauci AS, Kasper DL, Lango DL, Braunwald E, Hauser SL, Jameson JL, et al., editors. Harrison’s principles of internal medicine, 17th edn, vol 1. McGraw Hill; 2008 pp 1167–1168.
- WHO. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection (accessed 17 March 2015). Available from: http://www.who.int/hiv/pub/guidelines/arv2013/en/
- Balakrishnan P, Iqbal HS, Shanmugham S, et al. Low-cost assays for monitoring HIV infected individuals in resource-limited settings. Indian J Med Res. 2011;134:823–834.
- Braun J, Plantier J-C, Hellot M-F, et al. A new quantitative HIV load assay based on plasma virion reverse transcriptase activity for the different types, groups and subtypes. AIDS Lond Engl. 2003;17:331–336.
- Jennings C, Fiscus SA, Crowe SM, et al. Comparison of two human immunodeficiency virus (HIV) RNA surrogate assays to the standard HIV RNA assay. J Clin Microbiol. 2005;43:5950–5956.
- Iqbal HS, Balakrishnan P, Cecelia AJ, et al. Use of an HIV-1 reverse-transcriptase enzyme-activity assay to measure HIV-1 viral load as a potential alternative to nucleic acid-based assay for monitoring antiretroviral therapy in resource-limited settings. J Med Microbiol. 2007;56:1611–1614.
- Stevens G, Rekhviashvili N, Scott LE, et al. Evaluation of two commercially available, inexpensive alternative assays used for assessing viral load in a cohort of human immunodeficiency virus type 1 subtype C-infected patients from South Africa. J Clin Microbiol. 2005;43:857–861.
- Labbett W, Garcia-Diaz A, Fox Z, et al. Comparative evaluation of the Cavidi Load Version 3 Reverse Transcriptase Assay for measurement of human immunodeficiency virus type 1 plasma load. J Clin Microbiol. 2009;47:3266–3270.
- Huang D, Zhuang Y, Zhai S, et al. HIV reverse transcriptase activity assay: a feasible surrogate for HIV viral load measurement in China. Diagn Microbiol Infect Dis. 2010;68:208–213.
- ExaVir Load version 3.0. Quantitative determination of Reverse Transcriptase activity. Instructions for use. Cavidi, Uppsala, Sweden (accessed 17 March 2015). Available from: http://www.cavidi.se/wp-content/uploads/2014/06/ExaVir_Load_Instructions.pdf
- Qiagen. Qiagen Artus HIV-1 RG RT PCR. Handbook. Qiagen; 2012.
- Abbott RealTime HIV-1 PCR (accessed 17 March 2015). Available from: http://www.fda.gov/downloads/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/PremarketApprovalsPMAs/UCM091193.pdf
- BD FACS Count CD4 Reagents. Available from: https://www.bdbiosciences.com/documents/facscount_data_sheet.pdf
- Mermin J, Ekwaru JP, Were W, et al. Utility of routine viral load, CD4 cell count, and clinical monitoring among adults with HIV receiving antiretroviral therapy in Uganda: randomized trial. BMJ. 2011;343:d6792–d6792.
- Keiser O, MacPhail P, Boulle A, et al. Accuracy of WHO CD4 cell count criteria for virological failure of antiretroviral therapy. Trop Med Int Health. 2009;14:1220–1225.
- Kimmel AD, Weinstein MC, Anglaret X, et al. Laboratory monitoring to guide switching antiretroviral therapy in resource-limited settings: clinical benefits and cost-effectiveness. J Acquir Immune Defic Syndr. 2010;54:258–268.
- Wang S, Xu F, Demirci U. Advances in developing HIV-1 viral load assays for resource-limited settings. Biotechnol Adv. 2010;28:770–781.
- Crowe S, Turnbull S, Oelrichs R, Dunne A. Monitoring of human immunodeficiency virus infection in resource constrained countries. Clin Infect Dis. 2003;37:S25–S35.
- Annual report 2013-14-NACO, Department of Aids Control (accessed 17 March 2015). Available from: http://www.naco.gov.in/upload/2014%20mslns/NACO_English%202013-14.pdf
- Greengrass VL, Plate MM, Steele PM, et al. Evaluation of the Cavidi Load assay (version 3) for plasma human immunodeficiency virus type 1 load monitoring. J Clin Microbiol. 2009;47:3011–3013.
- Kokkayil P, Kurapati S, Negi N, Vajpayee M. Comparative evaluation of a reverse transcriptase based assay for HIV-1 viral load quantitation in resource limited settings. J Virol Methods. 2014;203:1–4.
- Stewart P, Cachafeiro A, Napravnik S, et al. Performance characteristics of the Cavidi ExaVir viral load assay and the ultra-sensitive P24 assay relative to the Roche Monitor HIV-1 RNA assay. J Clin Virol. 2010;49:198–204.
- Mine M, Bedi K, Maruta T, et al. Quantitation of human immunodeficiency virus type 1 viral load in plasma using reverse transcriptase activity assay at a district hospital laboratory in Botswana: a decentralization pilot study. J Virol Methods. 2009;159:93–97.
- Kandathil AJ, Kannangai R, Abraham OC, et al. The frequency of HIV-I drug resistance mutations among treatment-naive individuals at a tertiary care centre in south India. Int J STD AIDS. 2009;20:522–526.